Picard Medical Q1 revenue up 85% YoY; gross margin improves to 24%

Picard Medical, Inc.

Revenue for first three months of 2026 increased 85% YoY; U.S. revenue up 116%.
Gross margin improved to 24% from -4% in 2025.
Next-gen Emperor platform: pursuing FDA Breakthrough Device designation, IDE submission planned for 2028, clinical study in 2029.
Interim CEO Richard Fang acknowledges recent leadership changes but reaffirms mission.
Annual meeting set for July 17, 2026; proposals include director elections and capital structure amendments.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.